AstraZeneca resumes COVID vaccine trial, J&J could restart soon
Oct 26 2020
AstraZeneca (AZN) has gained approval by regulators to resume the trial of its experimental vaccine, while Johnson & Johnson (JNJ) is gearing up to continue its trial on Monday or Tuesday, the companies said.
Last week Kanta Subbarao, a World Health Organization (WHO) director explained the problem while saying that "early vaccine trials are not likely to show how well these products work in these populations".
AstraZeneca said the US Food and Drug Administration authorised the restart on Thursday after reviewing all of the global safety data and concluding it was safe to resume. Testing in Britain resumed that month.
"The restart of clinical trials across the world is great news as it allows us to continue our efforts to develop this vaccine to help defeat this awful pandemic", Pascal Soriot, AstraZeneca's CEO said in a statement.
Separately, the Canadian government is also providing up to $23.2 million in funding through the National Research Council of Canada Industrial Research Assistance Program to advance six COVID-19 vaccine candidates in various stages of clinical trials.
The pharmaceutical companies said the independent Data Safety and Monitoring Board (DSMB) approved the resumption of the clinical trial recruitments.
"At least 9 thousand volunteers were vaccinated in Brazil", says the statement of health care, "but the final result of the third clinical phase will be achieved only after the vaccination of 15 thousand subjects".
Netanyahu wished the scientists success at a cabinet meeting earlier in the day and said the government was also working to bring vaccines from overseas to be prepared. On October 2, the pharma company had applied to the Drugs Controller General of India (DCGI) asking its permission to conduct Phase 3 trials for its vaccine candidate.
The company is testing the only vaccine that aims to protect people with a single shot; other prospective vaccines require a return visit and second shot three to four weeks after the first to trigger a protective immune response. The woman was enrolled in the United Kingdom arm of the trial, which is run by the University of Oxford.
AstraZeneca said in a statement Friday that it isn't unusual for some participants to become unwell in large-scale vaccine trials.